138 related articles for article (PubMed ID: 36735902)
1. Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic-DEVD-Doxorubicin Conjugate for Targeted Cancer Therapy.
Yang SB; Lee DN; Lee JH; Seo M; Shin DW; Lee S; Lee YH; Park J
Bioconjug Chem; 2023 Feb; 34(2):333-344. PubMed ID: 36735902
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
Khaliq NU; Sandra FC; Park DY; Lee JY; Oh KS; Kim D; Byun Y; Kim IS; Kwon IC; Kim SY; Yuk SH
Biomaterials; 2016 Sep; 101():131-42. PubMed ID: 27286189
[TBL] [Abstract][Full Text] [Related]
3. Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy.
Um W; Park J; Ko H; Lim S; Yoon HY; Shim MK; Lee S; Ko YJ; Kim MJ; Park JH; Lim DK; Byun Y; Kwon IC; Kim K
Biomaterials; 2019 Dec; 224():119494. PubMed ID: 31542518
[TBL] [Abstract][Full Text] [Related]
4. Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity.
Shim MK; Yang S; Park J; Yoon JS; Kim J; Moon Y; Shim N; Jo M; Choi Y; Kim K
J Nanobiotechnology; 2022 Oct; 20(1):436. PubMed ID: 36195911
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
[TBL] [Abstract][Full Text] [Related]
6. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy.
Shim MK; Park J; Yoon HY; Lee S; Um W; Kim JH; Kang SW; Seo JW; Hyun SW; Park JH; Byun Y; Kwon IC; Kim K
J Control Release; 2019 Jan; 294():376-389. PubMed ID: 30550940
[TBL] [Abstract][Full Text] [Related]
7. Induced phenotype targeted therapy: radiation-induced apoptosis-targeted chemotherapy.
Lee BS; Cho YW; Kim GC; Lee DH; Kim CJ; Kil HS; Chi DY; Byun Y; Yuk SH; Kim K; Kim IS; Kwon IC; Kim SY
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505252
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
9. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
10. A pH-Sensitive Prodrug Nanocarrier Based on Diosgenin for Doxorubicin Delivery to Efficiently Inhibit Tumor Metastasis.
Wei Z; Wang H; Xin G; Zeng Z; Li S; Ming Y; Zhang X; Xing Z; Li L; Li Y; Zhang B; Zhang J; Niu H; Huang W
Int J Nanomedicine; 2020; 15():6545-6560. PubMed ID: 32943867
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers.
Jin Y; Wang Y; Liu X; Zhou J; Wang X; Feng H; Liu H
Drug Des Devel Ther; 2020; 14():5205-5215. PubMed ID: 33268983
[TBL] [Abstract][Full Text] [Related]
12. Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor.
Chung SW; Choi JU; Lee BS; Byun J; Jeon OC; Kim SW; Kim IS; Kim SY; Byun Y
Biomaterials; 2016 Jul; 94():1-8. PubMed ID: 27085176
[TBL] [Abstract][Full Text] [Related]
13. Screening of pH-responsive long-circulating polysaccharide-drug conjugate nanocarriers for antitumor applications.
Zhang X; Li D; Huang J; Ou K; Yan B; Shi F; Zhang J; Zhang J; Pang J; Kang Y; Wu J
J Mater Chem B; 2019 Jan; 7(2):251-264. PubMed ID: 32254550
[TBL] [Abstract][Full Text] [Related]
14. Assembly of polymer micelles through the sol-gel transition for effective cancer therapy.
Khaliq NU; Oh KS; Sandra FC; Joo Y; Lee J; Byun Y; Kim IS; Kwon IC; Seo JH; Kim SY; Yuk SH
J Control Release; 2017 Jun; 255():258-269. PubMed ID: 28456679
[TBL] [Abstract][Full Text] [Related]
15. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance.
Kim J; Shim MK; Yang S; Moon Y; Song S; Choi J; Kim J; Kim K
J Control Release; 2021 Feb; 330():920-932. PubMed ID: 33152391
[TBL] [Abstract][Full Text] [Related]
16. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
18. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency.
Li W; Fu J; Ding Y; Liu D; Jia N; Chen D; Hu H
Acta Biomater; 2019 Sep; 96():456-467. PubMed ID: 31260821
[TBL] [Abstract][Full Text] [Related]
19. Fabrication of redox-responsive doxorubicin and paclitaxel prodrug nanoparticles with microfluidics for selective cancer therapy.
Ma X; Özliseli E; Zhang Y; Pan G; Wang D; Zhang H
Biomater Sci; 2019 Jan; 7(2):634-644. PubMed ID: 30534690
[TBL] [Abstract][Full Text] [Related]
20. Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Wu Z; Li S; Cai Y; Chen F; Chen Y; Luo X
Colloids Surf B Biointerfaces; 2020 May; 189():110741. PubMed ID: 32032928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]